Arvind SmartSpaces Eyes ₹180 Crore Revenue from New Ahmedabad Housing Project

Source: Economictimes
Arth Insight · What this means for your wallet
- More Home Choices: If you're looking to buy a home in Ahmedabad, new projects like this increase your options in developing areas.
- Potential Property Value Impact: For existing homeowners near Kerala-Nalsarovar Road, increased development could influence your property's future value.
- Investment Opportunity Indicator: It highlights emerging real estate corridors in Ahmedabad, potentially offering new areas for property investment.
Real estate developer Arvind SmartSpaces has partnered with a local landowner for a new residential project on Ahmedabad's Kerala-Nalsarovar Road. The development is projected to generate ₹180 crore in revenue as the company expands its footprint in Gujarat.
- ▸Arvind SmartSpaces is launching a new housing project on Kerala-Nalsarovar Road in Ahmedabad.
- ▸The project is expected to bring in ₹180 crore in revenue through a partnership model.
- ▸The development highlights the growing demand for residential properties in Ahmedabad's outskirts.
- ✓Arvind SmartSpaces is launching a new housing project on Kerala-Nalsarovar Road in Ahmedabad.
- ✓The project is expected to bring in ₹180 crore in revenue through a partnership model.
- ✓The development highlights the growing demand for residential properties in Ahmedabad's outskirts.
Strategic Expansion in Ahmedabad
Arvind SmartSpaces Ltd, the real estate arm of the Lalbhai Group, has announced a new residential project in Ahmedabad, signaling robust growth in Gujarat's property market. The company has entered into a strategic partnership with a local landowner to develop a housing project on the Kerala-Nalsarovar Road corridor.
This move is part of the company's broader strategy to capitalize on the increasing demand for residential spaces in emerging suburban areas. By collaborating with a landowner, Arvind SmartSpaces follows an asset-light model, which typically helps developers reduce initial capital expenditure while focusing on construction and sales execution.
Financial Outlook and Market Reach
The developer anticipates that this new venture will unlock a revenue potential of approximately ₹180 crore. This project adds significant value to the company’s existing portfolio, which already features a mix of luxury villas, integrated townships, and mid-range residential apartments across major Indian cities.
The choice of Kerala-Nalsarovar Road is notable as the area is gaining traction for its connectivity and peaceful environment, making it a target for both investors and end-users looking for homes away from the city's central congestion.
Key Highlights of the Development
- Location: Situated on the Kerala-Nalsarovar Road, a growing residential hub in Ahmedabad.
- Revenue Goal: The project is estimated to generate ₹180 crore in sales.
- Model: A joint development partnership with a local landowner.
- Growth Strategy: Enhances Arvind SmartSpaces' presence in its home market of Gujarat.
As the real estate sector in Ahmedabad continues to show resilience, this project is expected to contribute to the city's urban sprawl, offering new options for home buyers in the burgeoning residential corridors.
Investment in real estate involves risks; revenue projections are estimates and not a guarantee of future performance. Consult a financial advisor before investing.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
Where exactly is the new project located?
The project is situated on the Kerala-Nalsarovar Road, an emerging residential corridor in Ahmedabad.
Who is developing this project?
It is being developed by Arvind SmartSpaces Ltd in partnership with a local landowner.
What is the expected financial scale of this project?
The company expects to generate approximately ₹180 crore in revenue from this specific development.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate

CCI Clears Advent International's ₹3,150 Crore Investment in Yatharth Hospitals
The Competition Commission of India (CCI) has approved Advent International's substantial ₹3,150 crore investment in Yatharth Hospitals through its affiliate, Rasmalai Limited. This deal will grant Advent a 24.9% minority stake in the healthcare provider. Yatharth Hospitals plans to utilize these funds for its expansion efforts and to enhance its healthcare network, buoyed by strong operational revenues and profit growth.
BreakingPiramal Pharma Slashes China Reliance to Under 10% for Supply Chain Resilience
Piramal Pharma has significantly reduced its dependence on Chinese raw materials to less than 10%. This strategic move aims to enhance supply chain resilience against geopolitical risks, with the company expanding its manufacturing footprint to India, the UK, and the US.

Dr Reddy's Pivots to Generic Semaglutide, Biosimilars for Future Growth
Dr Reddy's Laboratories is strategically focusing on the relaunch of generic semaglutide and expanding its biosimilars portfolio to drive future growth. This comes as the company navigates mixed results, with domestic formulations business growing but North American Revlimid sales declining in the September quarter.
Related Stories

CCI Clears Advent International's ₹3,150 Crore Investment in Yatharth Hospitals
The Competition Commission of India (CCI) has approved Advent International's substantial ₹3,150 crore investment in Yatharth Hospitals through its affiliate, Rasmalai Limited. This deal will grant Advent a 24.9% minority stake in the healthcare provider. Yatharth Hospitals plans to utilize these funds for its expansion efforts and to enhance its healthcare network, buoyed by strong operational revenues and profit growth.
BreakingPiramal Pharma Slashes China Reliance to Under 10% for Supply Chain Resilience
Piramal Pharma has significantly reduced its dependence on Chinese raw materials to less than 10%. This strategic move aims to enhance supply chain resilience against geopolitical risks, with the company expanding its manufacturing footprint to India, the UK, and the US.

Dr Reddy's Pivots to Generic Semaglutide, Biosimilars for Future Growth
Dr Reddy's Laboratories is strategically focusing on the relaunch of generic semaglutide and expanding its biosimilars portfolio to drive future growth. This comes as the company navigates mixed results, with domestic formulations business growing but North American Revlimid sales declining in the September quarter.

Aayush Wellness Launches Calcium & Vitamin D Tablets, Enters ₹1.35 Lakh Crore Bone Health Market
Aayush Wellness Limited has launched new calcium and vitamin D tablets, marking its entry into India's significant bone and joint health segment. This expansion reflects the growing consumer demand for preventive healthcare and nutritional supplements designed to support musculoskeletal health.